Corcept Therapeutics
CORT
$57.08
+11.57%
Corcept Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on discovering and developing medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the cortisol hormone. The company is a recognized leader in the hypercortisolism (Cushing's syndrome) market with its flagship drug Korlym, and it is transitioning into a broader oncology player. The current investor narrative is dominated by the recent FDA approval of its new cancer drug Lifyorli, a significant pipeline milestone that has driven renewed attention and debate around the stock's growth prospects beyond its core Cushing's syndrome business.…
CORT
Corcept Therapeutics
$57.08
Related headlines
CORT 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Corcept Therapeutics's 12-month outlook, with a consensus price target around $74.20 and implied upside of +30.0% versus the current price.
Average Target
$74.20
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$46 - $74
Analyst target range
Analyst coverage for CORT appears limited, with only two analysts providing estimates for future EPS and revenue, indicating this is a smaller-cap stock with less institutional following, which can lead to higher volatility. The consensus leans bullish, as evidenced by the institutional ratings data which shows a series of reiterated 'Buy' ratings from firms like HC Wainwright & Co. and Canaccord Genuity throughout 2025 and early 2026. The average revenue estimate for the next period is approximately $2.56 billion, with a wide range from $2.40 billion to $2.83 billion, reflecting significant uncertainty around the commercial uptake of its newly approved drug. The high target within this revenue range implies strong commercial success for Lifyorli, while the low target likely assumes more conservative adoption, highlighting the binary outcome typical of drug launches.
Bulls vs Bears: CORT Investment Factors
The evidence presents a sharply bifurcated picture, with the bull case powered by a transformative FDA catalyst and a pristine balance sheet, while the bear case highlights deteriorating core fundamentals and extreme volatility. Currently, the bullish momentum from the FDA approval is stronger, as reflected in the powerful 3-month price reversal of 28.97%. However, this is a sentiment-driven move that must now be validated by execution. The single most important tension in the investment debate is the race between Lifyorli's commercial ramp-up and the deceleration/margin pressure in the core Korlym business. The stock's fate over the next 12-18 months will be determined by which of these two opposing forces wins out.
Bullish
- FDA Approval for New Cancer Drug: The FDA approval of Lifyorli in late March 2026 is a transformative catalyst, expanding Corcept's commercial reach beyond Cushing's syndrome into oncology. This event triggered a powerful technical reversal, with the stock surging 22.49% in the past month and 28.97% over three months, breaking a longer-term downtrend. The approval validates the company's pipeline and opens a significant new revenue stream, with analyst revenue estimates for the next period ranging up to $2.83 billion.
- Robust Balance Sheet & Strong Cash Flow: The company has a fortress balance sheet with virtually no debt (Debt/Equity of 0.009) and strong liquidity (Current Ratio of 2.92). It generated $141.8 million in TTM free cash flow, providing ample internal capital to fund the commercial launch of Lifyorli and ongoing R&D without dilution. This financial strength significantly de-risks the investment during a critical commercial execution phase.
- Exceptionally High Gross Margins: Corcept's pharmaceutical business model yields gross margins of 98.74% (Q4 2025), a structural advantage that provides significant operating leverage. This allows a large portion of incremental revenue from Korlym and the new Lifyorli launch to flow through to the bottom line, supporting profitability even as the company invests in commercial expansion.
- Analyst Sentiment Bullish Post-Catalyst: Institutional analyst sentiment has turned positive following the FDA approval, with firms like HC Wainwright and Canaccord Genuity reiterating 'Buy' ratings. While coverage is limited (only 2 analysts providing estimates), the consensus view acknowledges the growth potential from Lifyorli, with the average revenue estimate for the next period at $2.56 billion, implying significant growth from the current ~$800M annual run-rate.
Bearish
- Revenue Growth Deceleration & Margin Pressure: Core business growth is slowing; Q4 2025 revenue of $202.1M was up only 11.12% YoY and declined sequentially from Q3's $207.6M. Concurrently, net margin compressed to 12.02% from 16.71% a year ago, indicating rising costs (likely SG&A for launch) are pressuring profitability despite high gross margins. This raises questions about the sustainability of earnings growth from the legacy Korlym franchise.
- Extreme Event-Driven Volatility: The stock exhibits extreme binary volatility characteristic of small-cap biotech, as evidenced by the catastrophic -71.85% max drawdown and the specific -50%+ plunge in a single day in late December 2025. This high-risk profile, coupled with a short ratio of 5.89, indicates significant speculative positioning and vulnerability to negative news or launch setbacks.
- High Valuation Relative to Slowing Growth: Even after the crash, the stock trades at a forward P/E of 32.0x and a P/S of 4.75x. With core revenue growth decelerating to 11% and net margins compressing, these multiples appear rich unless Lifyorla launch execution is flawless and rapid. The negative PEG ratio of -1.22 signals that the market is pricing in growth that recent fundamentals do not yet support.
- Commercial Execution Risk for New Drug: The investment thesis now hinges entirely on the successful commercial launch of Lifyorli in a competitive oncology market. Analyst revenue estimates for the next period show high uncertainty, with a wide range from $2.40B to $2.83B. Any missteps in market access, physician adoption, or reimbursement could lead to results at the low end of estimates, likely triggering another severe sell-off.
CORT Technical Analysis
The stock is in a pronounced downtrend over the past year, with a 1-year price change of -28.06%, but is currently experiencing a sharp recovery from its lows. As of the latest close at $51.42, the stock is trading at approximately 56.5% of its 52-week range ($28.66 to $91.0), indicating it has recovered from the bottom but remains significantly below its highs, suggesting a potential value opportunity if the recent positive catalyst holds. Recent momentum has been exceptionally strong, with a 1-month surge of 22.49% and a 3-month gain of 28.97%, dramatically diverging from the longer-term downtrend and signaling a powerful trend reversal likely driven by the FDA approval news. The stock's 52-week low of $28.66 and high of $91.0 provide clear technical boundaries; a sustained move above the recent recovery highs near $46-52 would signal continued bullish momentum, while a breakdown below the $28.66 low would invalidate the reversal. The stock exhibits high volatility, as evidenced by a dramatic price drop of over 50% in late December 2025, which underscores the binary event-driven nature typical of biotech stocks and necessitates careful risk management.
Beta
0.35
0.35x market volatility
Max Drawdown
-64.4%
Largest decline past year
52-Week Range
$29-$91
Price range past year
Annual Return
-19.1%
Cumulative gain past year
| Period | CORT Return | S&P 500 |
|---|---|---|
| 1m | +31.8% | +8.2% |
| 3m | +48.9% | +9.0% |
| 6m | -24.4% | +10.5% |
| 1y | -19.1% | +26.5% |
| ytd | +49.4% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CORT Fundamental Analysis
Revenue growth has been positive but decelerating recently; the most recent quarterly revenue was $202.1 million, representing an 11.12% year-over-year increase, but this follows a sequential decline from the prior quarter's $207.6 million. The company's net income for Q4 2025 was $24.3 million, translating to a net margin of 12.02%, demonstrating profitability, though this is down from a net margin of 16.71% in Q4 2024, indicating some margin compression. The gross margin remains exceptionally high at 98.74% for the quarter, a hallmark of its pharmaceutical business model. The balance sheet is robust with minimal financial risk; the debt-to-equity ratio is a negligible 0.0094, and the company generated $141.8 million in trailing twelve-month free cash flow, providing ample internal funding for its clinical pipeline. The current ratio of 2.92 indicates strong short-term liquidity, and the return on equity of 15.38% shows efficient use of shareholder capital.
Quarterly Revenue
$202125000.0B
2025-12
Revenue YoY Growth
+0.11%
YoY Comparison
Gross Margin
+0.98%
Latest Quarter
Free Cash Flow
$141785000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CORT Overvalued?
Given the company's positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 36.3x, while the forward P/E is 32.0x, with the forward discount suggesting the market anticipates modest earnings growth. Compared to sector averages (data not available in the provided set), a precise peer comparison cannot be quantified, but a P/E in the mid-30s is typical for profitable biotech firms with growth pipelines. Historically, the stock's own trailing P/E has fluctuated significantly, ranging from a low near 17.6x in late 2021 to a high of 146.5x in early 2025; the current 36.3x sits near the middle of this wide historical band, suggesting the market is pricing in a balanced view of growth prospects and execution risks post the recent catalyst.
PE
36.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 18x~147x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
75.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on the company's shifting profit profile. While gross margins are stellar at 98.7%, net margin has compressed from 16.7% to 12.0% YoY as SG&A costs likely rise to support the Lifyorli launch. Revenue growth has decelerated to 11.1% YoY and turned sequentially negative in Q4, indicating the core Cushing's business may be maturing. The investment case now depends on Lifyorli achieving the high end of analyst revenue estimates (~$2.8B) to justify the current forward P/E of 32x; failure to do so would expose the stock's high valuation relative to slowing underlying growth.
Market & Competitive Risks are pronounced. The stock's extreme volatility (max drawdown -71.85%) and high short interest (ratio 5.89) reflect a binary, event-driven profile highly sensitive to launch updates. Trading at a forward P/E of 32x and P/S of 4.75x, the valuation embeds significant success for Lifyorli, leaving it vulnerable to multiple compression if launch metrics disappoint. As a commercial-stage biotech, it faces intense competition in oncology and must execute flawlessly on market access and physician education. The stock has shown a low correlation to the broader market (1-year relative strength of -57.1% vs. SPY), meaning its risks are predominantly company-specific.
Worst-Case Scenario involves a botched Lifyorli launch characterized by slower-than-expected physician adoption, unfavorable reimbursement decisions, or emerging safety concerns. This could be coupled with a faster-than-anticipated decline in the Korlym franchise. Such a scenario would likely trigger analyst downgrades and a re-rating towards the stock's historical low P/E near 17.6x. The stock could realistically revisit its 52-week low of $28.66, implying a downside of approximately -44% from the current price of $51.42. The precedent of the -50% single-day drop in December 2025 demonstrates the market's capacity for severe, rapid repricing on negative developments.